Abstract：As an important drug during maintenance treatment of acute lymphoblastic leukemia (ALL), 6-mercaptopurine (6-MP) has several side effects, including hepatotoxicity and bone marrow suppression. Since its tolerability varies from person to person, 6-MP treatment should be individualized. The deficiency of thiopurine methyltransferase (TPMT) enzyme activity is associated with 6-MP intolerance. There is a lower frequency of mutation in TPMT alleles among Asian patients. Recent studies have shown that in ALL patients with NUDT15 gene mutation, the maximum tolerated dose of 6-MP is lower than the conventional dose. The article reviews the significance of NUDT15 gene in individualized treatment with 6-MP in children with ALL.
HE Jing,LIU Ling. Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia[J]. CJCP, 2019, 21(1): 100-104.
Lennard L, Cartwright CS, Wade R, et al. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003[J]. British J Haematol, 2015, 170(4):550-558.
[5]
Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity amongchildren with acute lymphoblastic leukemia[J].Current Haematol Malig Rep, 2017, 12(3):176-186.
[6]
Yi ES, Choi YB, Choi R, et al. NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia[J]. Cancer Res Treat, 2018, 50(3):872-882.
[7]
Singh M, Bhatia P, Khera S. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia[J]. Leuk Res, 2017, 62:17-22.
[8]
Zhu Y, Yin D, Su Y, et al. Combination of common and novel rare variants improves predictive sensitivity of thiopurine induced leukopenia in children with acute lymphoblastic leukemia[J]. Haematologica, 2018, 103(7):e293-e295.
[9]
Shah SA, Paradkar M, Desai D. Nucleoside diphosphatelinked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients[J]. J Gastroenterol Hepatol, 2017, 32(3):620-624.
[10]
Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia[J]. J Clin Oncol, 2015, 33(11):1235-1242.
Karran P, Attard N. Thiopurines in current medical practice:molecular mechanisms and contributions to therapy-related cancer[J]. Nat Rev Cancer, 2008, 8(1):24-36.
[13]
Takagi Y, Setoyama D, Ito R, et al. Human MTH3(NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates:comparison with MTH1 and MTH2[J]. J Biol Chem, 2012, 287(25):21541-21549.
[14]
Kim HT, Choi R, Won HH, et al. NUDT15 genotype distributions in the Korean population[J]. Pharmacogenet Genomics, 2017, 27(5):197-200.
[15]
Asada A, Nishida A, Shioya M, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease[J]. J Gastroenterol, 2016, 51(1):22-29.
[16]
Hashiguchi K, Hayashi M, Sekiguchi M, et al. The roles of human MTH1, MTH2 and MTH3 proteins in maintaining genome stability under oxidative stress[J]. Mutat Res, 2018, 808:10-19.
[17]
Singh M, Bhatia P, Khera S. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia[J]. Leuk Res, 2017, 62:17-22.
[18]
Moriyama T, Yang YL, Nishii R, et al. Novel variants inand thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry[J]. Blood, 2017, 130(10):1209-1212.
[19]
Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4):367-373.
[20]
Fong WY, Ho CC, Poon WT. Comparison of direct sequencing, real-time PCR-high resolution melt (PCR-HRM) and PCRrestriction fragment length polymorphism (PCR-RFLP) analysis for genotyping of common thiopurine intolerant variant alleles NUDT15 c415C>T and TPMT c719A>G (TPMT*3C)[J]. Diagnostics (Basel, Switzerland), 2017, 7(2):pii:E27.
[21]
Ho CC, Fong WY, Lee YH. Novel tetra-primer ARMS-PCR assays for thiopurine intolerance susceptibility mutations NUDT15 c415C>T and TPMT c719A>G (TPMT*3C) in East Asians[J]. Genes, 2017, 8(10):pii:E285.
[22]
Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia[J]. J Clin Oncol, 2015, 33(11):1235-1242.
[23]
Zhang AL, Yang J, Wang H, et al. Association of NUDT15 c.415C>T allele and thiopurine-induced leukocytopenia in Asians:a systematic review and meta-analysis[J]. Ir J Med Sc, 2018, 187(1):145-153.
[24]
Sato T, Takagawa T, Kakuta Y, et al. NUDT15, FTO and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases[J]. Intest Res, 2017, 15(3):328-337.
[25]
Kim H, Seo H, Park Y, et al. APEX1 polymorphism and mercaptopurine-related early onset neutropenia in pediatric acute lymphoblastic leukemia[J]. Cancer Res Treat, 2018, 50(3):823-834.
[26]
Soler AM, Olano N, Méndez Y, et al. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay[J]. Br J Haematol, 2018, 181(2):252-255.
[27]
Zgheib NK, Akika R, Mahfouz R, et al. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon[J]. Pediatr Blood Cancer, 2017, 64(1):146-150.
[28]
Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia[J]. Pharmacogenomics J, 2016, 16(6):536-539.
[29]
Zhu X, Wang XD, Chao K, et al. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease[J]. Aliment Pharmacol Ther, 2016, 44(9):967-975.
[30]
Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children:randomized trial from the Brazilian Childhood Cooperative Group——protocol ALL-99[J]. J Clin Oncol, 2010, 28(11):1911-1918.
[31]
Asada A, Nishida A, Shioya M, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease[J]. J Gastroenterol, 2016, 51(1):22-29.
[32]
Rudin S, Marable M, Huang RS, et al. The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment[J]. Genomics Proteomics Bioinformatics, 2017, 15(2):82-93.
[33]
Moriyama T, Nishii R, Lin TN, et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia[J]. Pharmacogenet Genomics, 2017, 27(6):236-239.
[34]
Lee YJ, Hwang EH, Park JH, et al. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease[J]. Eur J Gastroenterol Hepatol, 2016, 28(4):475-478.
[35]
Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia[J]. Br J Haematol, 2015, 171(1):109-115.
